Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of **bemarituzumab** (a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b, FGFR2b) with **mFOLFOX6** (a standard chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-fluorouracil) is an investigational therapy for first-line treatment of unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer (GC/GEJC) in patients with tumors that overexpress FGFR2b and are negative for HER2. Bemarituzumab inhibits FGFR2b, thereby suppressing tumor proliferation and promoting antibody-dependent cellular cytotoxicity. mFOLFOX6 acts as a cytotoxic chemotherapy regimen. The combination has shown clinically meaningful improvement in progression-free and overall survival compared to chemotherapy alone in phase 2 and phase 3 clinical trials for this patient population[1][2][3][4][5].
- Brand names
- none
- Other names
- bemarituzumab plus mFOLFOX6
02
Targets
FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on bemarituzumab + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab + mFOLFOX6.